Literature DB >> 9658074

Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells.

C A Pise-Masison1, M Radonovich, K Sakaguchi, E Appella, J N Brady.   

Abstract

Inhibition of p53 function, through either mutation or interaction with viral or cellular transforming proteins, correlates strongly with the oncogenic potential. Only a small percentage of human T-cell lymphotropic virus type 1 (HTLV-1)-transformed cells carry p53 mutations, and mutated p53 genes have been found in only one-fourth of adult T-cell leukemia cases. In previous studies, we demonstrated that wild-type p53 is stabilized and transcriptionally inactive in HTLV-1-transformed cells. Further, the viral transcriptional activator Tax plays a role in both the stabilization and inactivation of p53 through a mechanism involving the first 52 amino acids of p53. Here we show for the first time that phosphorylation of p53 inactivates p53 by blocking its interaction with basal transcription factors. Using two-dimensional peptide mapping, we demonstrate that peptides corresponding to amino acids 1 to 19 and 387 to 393 are hyperphosphorylated in HTLV-1-transformed cells. Moreover, using antibodies specific for phosphorylated Ser15 and Ser392, we demonstrate increased phosphorylation of these amino acids. Since HTLV-1 p53 binds DNA in a sequence-specific manner but fails to interact with TFIID, we tested whether phosphorylation of the N terminus of p53 affected p53-TFIID interaction. Using biotinylated peptides, we show that phosphorylation of Ser15 alone inhibits p53-TFIID interaction. In contrast, phosphorylation at Ser15 and -37 restores TFIID binding and blocks MDM2 binding. Our studies provide evidence that HTLV-1 utilizes the posttranslational modification of p53 in vivo to inactivate function of the tumor suppressor protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9658074      PMCID: PMC109779     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Retinal vasculitis in human T-lymphotropic virus type I associated myelopathy.

Authors:  K Sasaki; I Morooka; H Inomata; N Kashio; T Akamine; M Osame
Journal:  Br J Ophthalmol       Date:  1989-10       Impact factor: 4.638

3.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

4.  Arthritis in a human T lymphotropic virus type I (HTLV-I) carrier.

Authors:  S Ijichi; T Matsuda; I Maruyama; T Izumihara; K Kojima; T Niimura; Y Maruyama; S Sonoda; A Yoshida; M Osame
Journal:  Ann Rheum Dis       Date:  1990-09       Impact factor: 19.103

5.  Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein.

Authors:  C A Pise-Masison; K S Choi; M Radonovich; J Dittmer; S J Kim; J N Brady
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  Suppression of human colorectal carcinoma cell growth by wild-type p53.

Authors:  S J Baker; S Markowitz; E R Fearon; J K Willson; B Vogelstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

7.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53.

Authors:  W E Mercer; M T Shields; M Amin; G J Sauve; E Appella; J W Romano; S J Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

8.  Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

Authors:  A Gessain; F Barin; J C Vernant; O Gout; L Maurs; A Calender; G de Thé
Journal:  Lancet       Date:  1985-08-24       Impact factor: 79.321

9.  Infective dermatitis of Jamaican children: a marker for HTLV-I infection.

Authors:  L LaGrenade; B Hanchard; V Fletcher; B Cranston; W Blattner
Journal:  Lancet       Date:  1990-12-01       Impact factor: 79.321

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  41 in total

1.  Assessment of bovine leukemia virus transcripts in vivo.

Authors:  J Rovnak; J W Casey
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

3.  Planck-Benzinger thermal work function: thermodynamic characterization of the carboxy-terminus of p53 peptide fragments.

Authors:  Paul W Chun; Marc S Lewis
Journal:  Protein J       Date:  2010-11       Impact factor: 2.371

Review 4.  Effect of transforming viruses on molecular mechanisms associated with cancer.

Authors:  Tajhal Dayaram; Susan J Marriott
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

Review 5.  Human T-lymphotropic virus proteins and post-translational modification pathways.

Authors:  Carlo Bidoia
Journal:  World J Virol       Date:  2012-08-12

6.  Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor.

Authors:  Rami Aqeilan; Rotem Kedar; Ahmi Ben-Yehudah; Haya Lorberboum-Galski
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

7.  Evidence for NF-kappaB- and CBP-independent repression of p53's transcriptional activity by human T-cell leukemia virus type 1 Tax in mouse embryo and primary human fibroblasts.

Authors:  Akiko Miyazato; Sergey Sheleg; Hidekatsu Iha; Yan Li; Kuan-Teh Jeang
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

8.  Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation.

Authors:  C A Pise-Masison; R Mahieux; H Jiang; M Ashcroft; M Radonovich; J Duvall; C Guillerm; J N Brady
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 9.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 10.  Human T-cell leukemia virus type 1 Tax and cellular transformation.

Authors:  Jean-Marie Peloponese; Takao Kinjo; Kuan-Teh Jeang
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.